J-Pharma Co (TSE:520A) ROCE %: -81.54% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:520A J-Pharma Co Ltd TSE:520A
9 GF Score
Price 円290.00
View Full Analysis

What is J-Pharma Co ROCE %?

J-Pharma Co TSE:520A -2.36% 9 ROCE % is -81.54% as of Dec. 2025. GuruFocus rates TSE:520A with a GF Score™ of 9/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. J-Pharma Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -81.54%.

J-Pharma Co  (TSE:520A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

J-Pharma Co ROCE % Related Terms

J-Pharma Co ROCE % Historical Data

* Premium members only.

The historical data trend for J-Pharma Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

J-Pharma Co ROCE % Chart

J-Pharma Co Annual Data
Trend Mar24 Mar25
ROCE %
-162.21 -88.10

J-Pharma Co Quarterly Data
Mar24 Mar25 Dec25
ROCE % 0.00 0.00 -81.54
TSE:520A
9GF Score
J-Pharma Co Ltd TSE:520A
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

J-Pharma Co ROCE % Calculation

J-Pharma Co's annualized ROCE % for the fiscal year that ended in Mar. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2025 )  (A: Mar. 2024 )(A: Mar. 2025 )
=-1503.199/( ( (1207.393 - 199.703) + (2856.719 - 451.934) )/ 2 )
=-1503.199/( (1007.69+2404.785)/ 2 )
=-1503.199/1706.2375
=-88.10 %

J-Pharma Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Mar. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Mar. 2025 )(Q: Dec. 2025 )
=-1938.296/( ( (2856.719 - 451.934) + (2952.455 - 602.871) )/ 2 )
=-1938.296/( ( 2404.785 + 2349.584 )/ 2 )
=-1938.296/2377.1845
=-81.54 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -81.54% mean?
J-Pharma Co (TSE:520A) has a ROCE % of -81.54% as of Dec. 2025.
Is J-Pharma Co's ROCE % too high?
J-Pharma Co's current ROCE % is -81.54%. Overall, J-Pharma Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does J-Pharma Co's ROCE % compare to VRTX and REGN?
J-Pharma Co's ROCE % of -81.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. J-Pharma Co's current ROCE % is -81.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J-Pharma Co stock overvalued right now?
J-Pharma Co (TSE:520A) has a current ROCE % of -81.54%. The current ROCE % is -81.54%. J-Pharma Co's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For J-Pharma Co (TSE:520A), the current ROCE % is -81.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

J-Pharma Co Business Description

Address 1-10-11, HamamatsuCho, 8th floor, Minato-Ku, Tokyo, JPN, 105-0013
J-Pharma Co Ltd is engaged in the Drug discovery and development targeting SLC transporters. It is focused on a single segment of the drug discovery business, focusing on R&D and clinical development. The company's two compounds in clinical development are Nanbran Latte (JPH203) and JPH034.
9GF Score

Get the complete analysis for TSE:520A

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円290.00
Price